Focusing on other pathways, the following therapeutics were recommended: PARP inhibitors in 2 cases (due to one BRCA2 mutation in a CC patient and a BAP-1 mutation in a vulvar carcinoma patient), a PD-L1 inhibitor in 2 patients (due to one ARID1A mutation in a vulvar cancer and a high TMB in a vaginal cancer patient), a MEK/BRAF inhibitor in one CC patient (due to a BRAF mutation), an ALK/ROS1 inhibitor in one CC patient (due to a c-MET exon 14 skipping mutation) and an EGFR inhibitor in one vulvar cancer patient (due to an EGFR amplification). Here, BRCA2 is linked to vaginal cancer.